FIELD: medicine.
SUBSTANCE: there are offered versions of: a SSMA monoclonal antibody and its antigen-binding fragment which are bound with a mark or a cytotoxic agent. There are described versions of a pharmaceutical composition and a diagnostic kit based on such antibodies. There are disclosed methods for identification in vitro of tumour cells, as well as for diagnostic identification of tumour cells based on such antibodies. What is described is an isolated polynucleotide for producing monoclonal antibodies.
EFFECT: using the invention provides the antibodies which can bind SSMA in its native form on the surface of tumour cells, are bound with LNCAP, but are not bound with cells with lost SSMA expression that can find further application in prostate cancer therapy.
15 cl, 21 dwg, 3 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| BINDING MOLECULES, NAMELY ANTIBODIES CAPABLE OF BINDING TO L1CAM (CD171) | 2015 |
|
RU2754684C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| ANTIBODY POLYPEPTIDES AND THEIR APPLICATION | 2016 |
|
RU2753677C2 |
| HUMANIZED ANTIBODY TO CD52 | 2012 |
|
RU2605307C2 |
| RECOVERED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY AND METHOD OF INHIBITION OF PSMA-EXPRESSING CELL GROWTH | 2006 |
|
RU2421466C2 |
| ANTIBODIES TO THE RELATED CANCER-EMBRYONIC ANTIGEN CELL ADHESION MOLECULE (CEACAM) | 2012 |
|
RU2650869C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
